Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.

Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM.

J Clin Oncol. 2004 Dec 15;22(24):4951-7. Epub 2004 Dec 14.

PMID:
15598980
2.

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM.

Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Review.

PMID:
19020189
3.
4.

Chemoprevention of breast cancer for women at high risk.

Chan K, Morris GJ.

Semin Oncol. 2006 Dec;33(6):642-6. Review.

PMID:
17145342
5.

[Breast cancer chemoprevention. Rational, trials results and future].

Cutuli B, Lesur A, Namer M, Kerbrat P.

Bull Cancer. 2009 May;96(5):519-30. doi: 10.1684/bdc.2009.0855. Review. French.

6.
7.

Hot flashes and their management in breast cancer.

Carpenter JS.

Semin Oncol Nurs. 2000 Aug;16(3):214-25. Review.

PMID:
10967794
8.

The current status of breast cancer chemoprevention: a star is born.

Morrow M, Jordan VC.

J Surg Oncol. 2007 Jan 1;95(1):4-5. Review. No abstract available.

PMID:
17192883
9.

Breast cancer risk assessment and risk reduction.

Newman LA, Vogel VG.

Surg Clin North Am. 2007 Apr;87(2):307-16, vii-viii. Review.

PMID:
17498528
10.

Tamoxifen and breast cancer prevention: what should you tell your patients?

Goel V.

CMAJ. 1998 Jun 16;158(12):1615-7. Review. No abstract available.

11.

Clinical options for women at high risk for breast cancer.

Hartmann LC, Sellers TA, Schaid DJ, Nayfield S, Grant CS, Bjoraker JA, Woods J, Couch F.

Surg Clin North Am. 1999 Oct;79(5):1189-206. Review.

PMID:
10572558
12.

Chemoprevention of breast cancer: recommendations and rationale.

[No authors listed]

Am Fam Physician. 2003 Mar 15;67(6):1309-14. Review. No abstract available.

13.
14.

Potential role of tamoxifen in prevention of breast cancer.

Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS.

J Natl Cancer Inst. 1991 Oct 16;83(20):1450-9. Review.

PMID:
1920492
15.

Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.

Col NF, Chlebowski RT.

Menopause. 2008 Jul-Aug;15(4 Suppl):804-9. doi: 10.1097/gme.0b013e31817e5cce. Review.

PMID:
18596602
16.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force.

Ann Intern Med. 2005 Sep 6;143(5):362-79. Review. Erratum in: Ann Intern Med. 2005 Oct 4;143(7):547.

PMID:
16144895
17.

The cerebrovascular risks associated with tamoxifen use.

Bushnell C.

Expert Opin Drug Saf. 2005 May;4(3):501-7. Review.

PMID:
15934856
18.

Breast cancer risk assessment and prevention: a framework for shared decision-making consultations.

Ozanne EM, Klemp JR, Esserman LJ.

Breast J. 2006 Mar-Apr;12(2):103-13. Review.

PMID:
16509834
19.

Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.

Brown K.

Expert Opin Drug Saf. 2002 Sep;1(3):253-67. Review.

PMID:
12904141
20.

Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review.

Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM.

Med J Aust. 2003 Jan 20;178(2):77-81. Review.

PMID:
12526728

Supplemental Content

Support Center